Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects.
Smith
I E
IE
Breast Unit, Section of Medicine, Royal Marsden Hospital, London, UK.
Norton
A
A
D018931:Antineoplastic Agents, Hormonal / Q000493:pharmacokinetics / Q000494:pharmacology*; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology*; D017316:Fadrozole / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D000077289:Letrozole; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000378:metabolism*; D009570:Nitriles / Q000493:pharmacokinetics / Q000494:pharmacology*; D016032:Randomized Controlled Trials as Topic; D014230:Triazoles / Q000493:pharmacokinetics / Q000494:pharmacology*
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D009570:Nitriles; D014230:Triazoles; D000077289:Letrozole; D017316:Fadrozole